Expansion of regenerative medicine business using cardiac cell sheets and progress in research and development

Overview of the business

Qualips is advancing research, development, and business deployment of regenerative medicine using cardiac muscle cell sheets, obtaining manufacturing and sales approvals domestically and internationally, and concluding research contracts. By March 2026, domestic manufacturing and sales approval is expected to be obtained, accelerating preparations for clinical applications. In research, the aim is to realize next-generation medicine through physician-led clinical trials and joint research agreements, collaborating with medical and research institutions domestically and overseas. Going forward, the company will promote development and practical implementation of new therapies, pursuing innovation in the medical field.

Outlook and impact for investors

Going forward, the plan is to accelerate product commercialization alongside expansion of clinical trials domestically and internationally. In particular, starting with domestic approval in 2026, the company aims to broaden its business overseas. Advances in research contracts and clinical trials are expected to increase future sales and strengthen the business foundation, enhancing the company's reputation as a contributor to medical innovation. For investors, this presents opportunities for participation in growth in the medical field and innovative technologies, with strong mid- to long-term growth potential.